• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA• Launch preparations are underway to bring the second approved golimumab biosimilar to patients acro...
View DetailsThe U.S. Food and Drug Administration (FDA)has accepted Bio-Thera’s Biologics License Applications (BLA) for BAT2206 as aninterchangeable biosimilar to reference product Stelara® The European Medicines Agency (EMA) hasaccepted the Marketing Authoriza...
CHMP positive opinion is based on a robustanalytical, non-clinical and clinical data package comparing Avzivi® to thereference product Avastin® Guangzhou, China– June 3, 2024 –Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceutica...
Guangzhou, China– June 2 , 2024 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will present aposter at the 2024 ASCO Annual Meeting entitled “Phase 1 s...
